Form 4 for DSS DSS, INC.

Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-06 · accession 0001493152-25-005715 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2025-02-10	2025-02-06	DSS	Chan Heng Fai Ambrose	Dir, 10%	A - Grant	$0.00	+1.00M	1.00M	+33,580%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-06	A	A	1,000,000	$0.00	1,002,978	I See footnote	—	—	(F1) On February 6, 2025, the Issuer awarded Mr. Heng Fai Ambrose Chan, a Director of the Company, a stock grant of 1,000,000 newly issued shares of the Issuer's common stock through his personally owned company, Heng Fai Holdings Limited as compensation for services rendered. The common stock was issued pursuant to the Issuer's 2020 Employee, Director and Consultant Equity Incentive Plan. (F2) The beneficial ownership of Mr. Chan includes a total of 6,148,664 shares of common stock, consisting of (a) 1,002,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).